Información:
Error:
ID
35055
Descripción
Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02483767
Link
https://clinicaltrials.gov/show/NCT02483767
Palabras clave
Versiones (1)
- 12/2/19 12/2/19 -
Titular de derechos de autor
See clinicaltrials.gov
Subido en
12 de febrero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Breast Cancer NCT02483767
Eligibility Breast Cancer NCT02483767
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT02483767
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Informed Consent
Item
the patients signed the written informed consent.
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma TNM Breast tumor staging
Item
histologically proven stage i, ii, or iii breast cancer
boolean
C0678222 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
C0474926 (UMLS CUI [1,2])
Patients Appropriate Adjuvant Chemotherapy | Patients Appropriate Chemotherapy Neoadjuvant
Item
must be candidates for adjuvant or neoadjuvant chemotherapy,
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0085533 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1298676 (UMLS CUI [2,4])
C1548787 (UMLS CUI [1,2])
C0085533 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1298676 (UMLS CUI [2,4])
Premenopausal state
Item
must be premenopausal.
boolean
C0232969 (UMLS CUI [1])
trastuzumab | Tumor HER2 Overexpression
Item
trastuzumab is permitted in patients with human epidermal growth factor receptor 2 (her2) overexpressing tumors.
boolean
C0728747 (UMLS CUI [1])
C0027651 (UMLS CUI [2,1])
C0069515 (UMLS CUI [2,2])
C1514559 (UMLS CUI [2,3])
C0027651 (UMLS CUI [2,1])
C0069515 (UMLS CUI [2,2])
C1514559 (UMLS CUI [2,3])
Prior Chemotherapy
Item
the patients were previous chemotherapy;
boolean
C1514457 (UMLS CUI [1])
Distant metastasis
Item
evidence of distant metastases;
boolean
C1269798 (UMLS CUI [1])
Cancer Other
Item
other malignancies in the previous 5 years.
boolean
C1707251 (UMLS CUI [1])
Gonadotropin releasing hormone agonists (GNRH-A) | Progesterone | Ovulation Stimulation Drugs | Contraceptives, Oral | Aromatase Inhibitors | Intrauterine Devices Hormonal | Subcutaneous contraceptive | Hormone Therapy Drugs
Item
the patients were using gnrha, progesterone, stimulate ovulation drugs, oral contraceptives, aromatase inhibitors, intrauterine device with hormone, subcutaneous preparations contraceptive drugs such as hormone drugs and instruments during 3 month preceding the start of chemotherapy.
boolean
C2012324 (UMLS CUI [1])
C0033308 (UMLS CUI [2])
C0029965 (UMLS CUI [3,1])
C1292856 (UMLS CUI [3,2])
C0013227 (UMLS CUI [3,3])
C0009905 (UMLS CUI [4])
C0593802 (UMLS CUI [5])
C0021900 (UMLS CUI [6,1])
C0458083 (UMLS CUI [6,2])
C0459222 (UMLS CUI [7])
C0279025 (UMLS CUI [8,1])
C0013227 (UMLS CUI [8,2])
C0033308 (UMLS CUI [2])
C0029965 (UMLS CUI [3,1])
C1292856 (UMLS CUI [3,2])
C0013227 (UMLS CUI [3,3])
C0009905 (UMLS CUI [4])
C0593802 (UMLS CUI [5])
C0021900 (UMLS CUI [6,1])
C0458083 (UMLS CUI [6,2])
C0459222 (UMLS CUI [7])
C0279025 (UMLS CUI [8,1])
C0013227 (UMLS CUI [8,2])
Pregnancy | Breast Feeding
Item
pregnancy or lactation.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])